Obesity and Cancer – Presented by: Majula Gupta, PhD

08/01/16 2:30 PM - 08/01/16 4:00 PM
Philadelphia Convention Center, North Broad Street, Philadelphia, PA, United States Philadelphia Convention Center, North Broad Street, Philadelphia, PA, United States

CE Hours: 1.5 Hours

Session Level: Advanced

Session Overview: About 30-35% adults in the US are obese. Obesity carries a significant risk for cancer development and progression. Recent studies suggest that dysregulated hormones from adipose tissue lead to insulin resistance via secretion of pro-inflammatory cytokines and adipokines. One of the major adipokines, leptin, is known to play a central role in obesity-related cancer. Recent findings on molecular mechanisms of leptin and adiponectin will be discussed.

Needs Assessment: Obesity has long been recognized as a cause of many metabolic disorders like type 2 diabetes, heart disease and hypertension. However, its association with different types of cancers as evidenced by epidemiological studies is less recognized than cardiovascular disease. The mechanisms by which obesity induces and promotes carcinogenesis differs by cancer type and includes insulin resistance and resulted hyperinsulinemia (1). Insulin resistance in obesity develops as metabolic adaptation to increased level of free fatty acids released from adipose tissues leading to hyperinsulinemia, hormone deregulation and inflammation that have been associated with increased risk of various cancer types. Among the inflammatory molecules adipokine leptin primarily produced by adippose tissue has been reported as a key factor for cancer growth in in-vitro studies. Cancer cells have been shown to over-express leptin receptor and pro-angiogenic, pro-inlammatory and mitogenic actions of leptin have been reported to play a central role in obesity related cancers (2). References: 1) Nature Reviews Cancer (2004) 4:579- 591 2) Endocrine Related Cancer (2011) 18:C25-C29

Intended Audience: This session is intended for: clinical pathologists/chemists, lab directors, industry scientists, and technologists

Expected Outcome: After attending this session, participants will be able to: 1) identify the prevalence of obesity and its association with cancer; 2) outline the mechanisms of hormone dysregulation in obesity; 3) identify the markers of insulin resistance and their role in increased risk of cancer; 4) define adipokines; and (5) list the pro-carcinogenic effects and molecular mechanisms of leptin


Manjula Gupta, PhD, Cleveland Clinic Foundation, Moderator
Epidemiology and Proposed Mechanisms [Insulin Resistance] in Obesity and Cancer

Ofer Reizes, PhD, Cleveland Clinic
Role of Leptin Signaling in Cancer Development and Progression